PET/CT Imaging of Chemokine Receptors in Inflammatory Atherosclerosis Using Targeted Nanoparticles

Atherosclerosis is inherently an inflammatory process that is strongly affected by the chemokine–chemokine receptor axes regulating the trafficking of inflammatory cells at all stages of the disease. Of the chemokine receptor family, some specifically upregulated on macrophages play a critical role in plaque development and may have the potential to track plaque progression. However, the diagnostic potential of these chemokine receptors has not been fully realized. On the basis of our previous work using a broad-spectrum peptide antagonist imaging 8 chemokine receptors together, the purpose of this study was to develop a targeted nanoparticle for sensitive and specific detection of these chemokine receptors in both a mouse vascular injury model and a spontaneously developed mouse atherosclerosis model. Methods: The viral macrophage inflammatory protein-II (vMIP-II) was conjugated to a biocompatible poly(methyl methacrylate)-core/polyethylene glycol-shell amphiphilic comblike nanoparticle through controlled conjugation and polymerization before radiolabeling with 64Cu for PET imaging in an apolipoprotein E–deficient (ApoE−/−) mouse vascular injury model and a spontaneous ApoE−/− mouse atherosclerosis model. Histology, immunohistochemistry, and real-time reverse transcription polymerase chain reaction were performed to assess the plaque progression and upregulation of chemokine receptors. Results: The chemokine receptor–targeted 64Cu-vMIP-II-comb showed extended blood retention and improved biodistribution. PET imaging showed specific tracer accumulation at plaques in ApoE−/− mice, confirmed by competitive receptor blocking studies and assessment in wild-type mice. Histopathologic characterization showed the progression of plaque including size and macrophage population, corresponding to the elevated concentration of chemokine receptors and more importantly increased PET signals. Conclusion: This work provides a useful nanoplatform for sensitive and specific detection of chemokine receptors to assess plaque progression in mouse atherosclerosis models.

[1]  D. Greaves,et al.  Chemokines, Chemokine Receptors and Atherosclerosis , 2005 .

[2]  Michael J Welch,et al.  Nanoparticles labeled with positron emitting nuclides: advantages, methods, and applications. , 2012, Bioconjugate chemistry.

[3]  A. Zernecke,et al.  Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. , 2006, Blood.

[4]  F. Mach,et al.  Differential Expression Patterns of Proinflammatory and Antiinflammatory Mediators During Atherogenesis in Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[5]  G. Randolph,et al.  Local apoptosis mediates clearance of macrophages from resolving inflammation in mice. , 2013, Blood.

[6]  J. Jukema,et al.  Chemokines and atherosclerotic plaque progression: towards therapeutic targeting? , 2007, Current pharmaceutical design.

[7]  W. Kuziel,et al.  CC chemokine receptor 5 influences late-stage atherosclerosis. , 2007, Atherosclerosis.

[8]  Craig J Hawker,et al.  Nanoparticle PET/CT imaging of natriuretic peptide clearance receptor in prostate cancer. , 2013, Bioconjugate chemistry.

[9]  Christian Weber,et al.  Chemokines in Atherosclerosis , Thrombosis , and Vascular Biology Series Editor : Christian Weber Chemokines in Atherosclerosis An Update , 2008 .

[10]  Oliver Soehnlein,et al.  Chemokines control mobilization, recruitment, and fate of monocytes in atherosclerosis. , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[11]  R. Ross,et al.  Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[12]  Joel A. Cohen,et al.  Impact of hydrogel nanoparticle size and functionalization on in vivo behavior for lung imaging and therapeutics. , 2009, Molecular pharmaceutics.

[13]  D. Wagner,et al.  Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. , 2000, Circulation.

[14]  F. Mach,et al.  The specific role of chemokines in atherosclerosis , 2007, Thrombosis and Haemostasis.

[15]  D. Greaves,et al.  The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics , 2004, Current opinion in lipidology.

[16]  Eric D. Pressly,et al.  Targeting Angiogenesis Using a C-Type Atrial Natriuretic Factor–Conjugated Nanoprobe and PET , 2011, The Journal of Nuclear Medicine.

[17]  Sébastien Perrier,et al.  Macromolecular design via réversible addition-fragmentation chain transfer (RAFT)/Xanthates (MADIX) polymerization , 2005 .

[18]  Yiran Wang,et al.  C‐Terminal Incorporation of Bio‐Orthogonal Azide Groups into a Protein and Preparation of Protein–Oligodeoxynucleotide Conjugates by CuI‐Catalyzed Cycloaddition , 2007, Chembiochem : a European journal of chemical biology.

[19]  M. Jerath,et al.  Chemokine Receptors in Atherosclerosis , 2007 .

[20]  R. Pierce,et al.  PET Imaging of Chemokine Receptors in Vascular Injury–Accelerated Atherosclerosis , 2013, The Journal of Nuclear Medicine.

[21]  R. Horuk,et al.  Chemokine receptor antagonists: overcoming developmental hurdles , 2009, Nature Reviews Drug Discovery.

[22]  A. Zernecke,et al.  Chemokines in the vascular inflammatory response of atherosclerosis. , 2010, Cardiovascular research.

[23]  F. Tacke,et al.  Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. , 2007, The Journal of clinical investigation.

[24]  R. Horuk,et al.  Promiscuous drugs as therapeutics for chemokine receptors , 2009, Expert Reviews in Molecular Medicine.

[25]  Eric D. Pressly,et al.  PET/CT Imaging of Chemokine Receptor CCR5 in Vascular Injury Model Using Targeted Nanoparticle , 2014, The Journal of Nuclear Medicine.

[26]  D. Greaves,et al.  CC Chemokine Receptors and Chronic Inflammation—Therapeutic Opportunities and Pharmacological Challenges , 2013, Pharmacological Reviews.

[27]  A. Zernecke,et al.  Molecular Imaging of Inflammation in Atherosclerosis , 2013, Theranostics.

[28]  D. Ly,et al.  Nanoparticle for delivery of antisense γPNA oligomers targeting CCR5 , 2013, Artificial DNA, PNA & XNA.

[29]  J. Rudd,et al.  PET imaging of inflammation in atherosclerosis , 2014, Nature Reviews Cardiology.

[30]  F. Mach,et al.  Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. , 2006, Atherosclerosis.

[31]  R. Westrick,et al.  Murine models of vascular thrombosis (Eitzman series). , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[32]  R. Ransohoff,et al.  The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.

[33]  D. Rader,et al.  Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression. , 2011, The Journal of clinical investigation.

[34]  Ralph Weissleder,et al.  Nanoparticle PET-CT Imaging of Macrophages in Inflammatory Atherosclerosis , 2008, Circulation.

[35]  P. Libby Inflammation in atherosclerosis , 2002, Nature.

[36]  K. Moore,et al.  Macrophages in atherosclerosis: a dynamic balance , 2013, Nature Reviews Immunology.

[37]  Daniel G. Anderson,et al.  Therapeutic siRNA silencing in inflammatory monocytes , 2011, Nature Biotechnology.